OWP
VRNA

ORG Wealth Partners’s Verona Pharma VRNA Stock Holding History

ORG Wealth Partners’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-123
Closed -$11.1K – 714
2025
Q2 		$11.1K Hold
123
– – ﹤0.01% 479
2025
Q1 		$7.2K Sell
123
-8
-6% -$479 ﹤0.01% 570
2024
Q4 		$6.08K Hold
131
– – ﹤0.01% 403
2024
Q3 		$3.77K Buy
+131
New +$3.22K ﹤0.01% 421

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ORG Wealth Partners's VRNA Position: Q3 2025 in Review

ORG Wealth Partners sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 123 shares — an estimated $11.1K sold.

ORG Wealth Partners first reported a position in VRNA in Q3 2024 and held it in 4 quarters. The position peaked at $11.1K in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • ORG Wealth Partners reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • ORG Wealth Partners sold 123 Verona Pharma shares in Q3 2025, an estimated $11.1K.
  • ORG Wealth Partners first reported a position in Verona Pharma in Q3 2024 and held it in 4 quarters.
  • ORG Wealth Partners's Verona Pharma position peaked at $11.1K in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on ORG Wealth Partners's 13F filing for Q3 2025, filed 24 Oct 2025.